Association of a T262C transition in exon 1 of estrogen-receptor-α gene with skeletal responsiveness to estrogen in post-menopausal women

被引:14
作者
Ongphiphadhanakul, B [1 ]
Chanprasertyothin, S [1 ]
Payattikul, P [1 ]
Saetung, S [1 ]
Piaseu, N [1 ]
Chailurkit, L [1 ]
Chansirikarn, S [1 ]
Puavilai, G [1 ]
Rajatanavin, R [1 ]
机构
[1] Mahidol Univ, Ramathibodi Hosp, Dept Med, Div Endocrinol & Metab, Bangkok 10400, Thailand
关键词
osteoporosis; bone mass; estrogen-receptor-alpha gene; genetics; estrogen responsiveness;
D O I
10.1007/BF03343923
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polymorphic genetic markers of estrogen-receptor-alpha (ER alpha) gene studied so far in osteoporosis reside in non-coding region with uncertain functional significance. The purpose of the present study was to search for nucleotides changes in the exon 1 and 5' regulatory region of ER alpha gene, to study the nature of their linkages to the previously reported Pvull polymorphism in intron 1 and their functional significance in postmenopausal osteoporosis. Direct sequencing of exon 1 and promotor region of ER alpha gene revealed a synonymous nucleotide substitution from T to C at position 262, 29 nucleotides downstream from the putative start codon. No nucleotide change was found in the promotor region. Linkage disequilibrium between the T262C polymorphism and the Pvull polymorphism in intron 1 of ER alpha gene was demonstrated in 129 post-menopausal women (p <0.001). After treating 96 post-menopausal with 0.3 mg or 0.625 mg conjugated equine estrogen (CEE) for 2 yr, vertebral bone mineral density (BMD) increased regardless of the T262C genotype. However, with regard to femoral neck BMD, only those subjects that were homozygous for the T262C polymorphism had an increase in femoral BMD (+5.9 +/-1.4%, mean +/- SE; p <0.0001). Using analysis of covariance to assess the effects of the T262C polymorphism, the intronic Pvull polymorphism, doses of CEE and the corresponding baseline BMD on the changes in vertebral or femoral BMD after treatments, it was found that the change in vertebral BMD was related only to the baseline BMD (p <0.05). The change in femoral BMD was independently related to the T262C polymorphism (p <0.01) and the baseline femoral BMD (p <0.01). No effect of the Pvull polymorphism or the doses of CEE on femoral BMD was demonstrated. We concluded that the previously described intronic Pvull polymorphism of ER alpha gene is in linkage disequilibrium with a T262C polymorphism in exon 1. This T262C polymorphism appears to be more directly related to the skeletal response after long-term treatment with estrogen. (C) 2001, Editrice Kurtis.
引用
收藏
页码:749 / 755
页数:7
相关论文
共 34 条
[1]   Kozak sequence polymorphism of the glycoprotein (GP) Ibα gene is a major determinant of the plasma membrane levels of the platelet GP Ib-IX-V complex [J].
Afshar-Kharghan, V ;
Li, CQ ;
Khoshnevis-Asl, M ;
López, JA .
BLOOD, 1999, 94 (01) :186-191
[2]   Vitamin D receptor gene Fok1 polymorphism predicts calcium absorption and bone mineral density in children [J].
Ames, SK ;
Ellis, KJ ;
Gunn, SK ;
Copeland, KC ;
Abrams, SA .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (05) :740-746
[3]   A vitamin D receptor gene polymorphism in the translation initiation codon: Effect on protein activity and relation to bone mineral density in Japanese women [J].
Arai, H ;
Miyamoto, KI ;
Taketani, Y ;
Yamamoto, H ;
Iemori, Y ;
Morita, K ;
Tonai, T ;
Nishisho, T ;
Mori, S ;
Takeda, E .
JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (06) :915-921
[4]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[5]   Effects of hormone therapy on bone mineral density - Results from the postmenopausal estrogen/progestin interventions (PEPI) trial [J].
Bush, TL ;
Wells, HB ;
James, MK ;
BarrettConnor, E ;
Marcus, R ;
Greendale, G ;
Hunsberger, S ;
McGowan, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (17) :1389-1396
[6]   CALCIUM-ABSORPTION ON HIGH AND LOW-CALCIUM INTAKES IN RELATION TO VITAMIN-D-RECEPTOR GENOTYPE [J].
DAWSONHUGHES, B ;
HARRIS, SS ;
FINNERAN, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (12) :3657-3661
[7]   Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes [J].
Deng, HW ;
Li, J ;
Li, JL ;
Johnson, M ;
Gong, G ;
Davis, KM ;
Recker, RR .
HUMAN GENETICS, 1998, 103 (05) :576-585
[8]   The benefit of hormone replacement therapy on bone mass is greater at the vertebral body than posterior processes or proximal femur [J].
Duan, Y ;
Tabensky, A ;
DeLuca, V ;
Seeman, E .
BONE, 1997, 21 (05) :447-451
[9]   Lack of correlation between start codon polymorphism of the vitamin D receptor gene and bone mineral density in premenopausal French women: The OFELY study [J].
Eccleshall, TR ;
Garnero, P ;
Gross, C ;
Delmas, PD ;
Feldman, D .
JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (01) :31-35
[10]   POSTMENOPAUSAL BONE LOSS IS PREVENTED BY TREATMENT WITH LOW-DOSAGE ESTROGEN WITH CALCIUM [J].
ETTINGER, B ;
GENANT, HK ;
CANN, CE .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (01) :40-45